Selected article for: "acute sars cov respiratory syndrome coronavirus and low middle"

Author: Baay, Marc; Neels, Pieter
Title: SARS-CoV-2 controlled human infection models: Ethics, challenge agent production and regulatory issues
  • Cord-id: hcphw6ka
  • Document date: 2020_8_15
  • ID: hcphw6ka
    Snippet: This second International Alliance for Biological Standardization COVID-19 webinar brought together a broad range of international stakeholders, including academia, regulators, funders and industry, with a considerable participation from low- and middle-income countries, to discuss the use of controlled human infection models to accelerate development and market authorization assessment of a vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Document: This second International Alliance for Biological Standardization COVID-19 webinar brought together a broad range of international stakeholders, including academia, regulators, funders and industry, with a considerable participation from low- and middle-income countries, to discuss the use of controlled human infection models to accelerate development and market authorization assessment of a vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

    Search related documents:
    Co phrase search for related documents
    • absence presence and adjuvant vaccine: 1, 2, 3
    • absence presence and living people: 1, 2, 3, 4, 5
    • academic private and access information: 1, 2
    • academic private and living people: 1
    • access information and living people: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • adaptation evolution and living people: 1
    • additional concern and living people: 1
    • additional safety and adjuvant vaccine: 1